Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
405 Leser
Artikel bewerten:
(1)

Agfa-Gevaert publishes its third quarter 2018 results - Regulated information - November 7, 2018 - 7:45 a.m. CET

· Top line decline of 4.8%, excluding currency effects and the impact of portfolio rationalizations

· Strong performance of Inkjet, HealthCare Information Solutions and certain Specialty Products ranges

· Recurring EBITDA at 35 million Euro

· Net loss at minus 5 million Euro

· Net financial debt at 99 million Euro

Mortsel (Belgium), November 7, 2018 - Agfa-Gevaert today announced its third quarter 2018 results.
"During this quarter, we continued to make excellent progress with the reorganization of our HealthCare IT activities into a stand-alone legal entity structure within the Group. The technical part of this complex exercise is almost behind us. We have also been focusing on clarifying the strategies of the future HealthCare IT company, as well as of the other activities of the Group. As already stated before, we aim at playing an important role in the consolidation of the offset industry. This strategy has translated into concrete actions in the past quarter. We entered into an alliance with the Chinese Lucky HuaGuang Graphics Co. Ltd., which will have far-reaching consequences for our business and for the prepress industry. Furthermore, we announced our intention to acquire the prepress business of the Spanish Ipagsa company. Finally, in order to optimize production capacity, we recently announced the intended closure of our printing plate factory in Branchburg.
I am confident that when the project is completed, two companies will emerge that will have the power and the means to pursue growth in the years to come. We will give more information on how we see the companies' structures and strategies when we report on our full year results.
The strong third quarter performance of most of our growth engines was snowed under by the top line decrease of most of our traditional businesses. As expected, the top line of Agfa Graphics' prepress business was impacted by the product portfolio reorganization. In Agfa HealthCare, the hardcopy business temporarily slowed down following a marked recovery in the first half of the year. However, we are confident that this business will pick up again in the coming quarters.
Our full year recurring EBITDA margin will be around 8% of revenue. Mainly based on our current actions in the field of the prepress and HealthCare IT businesses, we stick to our ambition to target a recurring EBITDA margin of around 10% of revenue on average in the years to come," said Christian Reinaudo, President and CEO of the Agfa-Gevaert Group.

Agfa-Gevaert Group - third quarter 2018

in million EuroQ3 2017Q3 2018% change
(excl. FX effects)
Revenue 593 539 -9.1% (-7.9%)
Gross profit (*) 195 171 -12.1%
% of revenue 32.9% 31.8%
Recurring EBITDA (*) 53 35 -34.3%
% of revenue 9.0% 6.5%
Recurring EBIT (*) 40 21 -47.0%
% of revenue 6.8% 4.0%
Result from operating activities 31 6 -79.2%
Result for the period 14 (5)
Net cash from (used in) operating activities 18 (15)

(*) before restructuring and non-recurring items

The Agfa-Gevaert Group's top line evolution was strongly impacted by the product portfolio reorganization in the Agfa Graphics business group's prepress business.
Excluding portfolio rationalizations and currency effects, the Agfa-Gevaert Group's revenue decline amounted to 4.8%. Several growth engines - including Agfa Graphics' inkjet business, Agfa HealthCare's HealthCare Information Solutions and several activities of Agfa Specialty Products - posted strong topline growth.

Mainly due to high aluminum prices and adverse product/mix effects, the Group's gross profit margin decreased to 31.8% of revenue.

As a percentage of revenue, Selling and General Administration expenses increased to 21.4% of revenue.

R&D expenses amounted to 32 million Euro, or 6.0% of revenue.

Recurring EBITDA reached 6.5% of revenue, versus 9.0% in the third quarter of 2017. Recurring EBIT reached 4.0% of revenue.

Partly due to costs related to the transformation of the Company, restructuring and non-recurring items resulted in an expense of 15 million Euro, versus an expense of 9 million Euro in the previous year.

The net finance costs increased from 8 million Euro in the third quarter of 2017 to 11 million Euro.

Income tax expenses decreased to 0 million Euro.

As a result of the elements mentioned above, the Agfa-Gevaert Group posted a net loss of 5 million Euro.

Financial position and cash flow

  • At the end of the third quarter of 2018, total assets were 2,348 million Euro, compared to 2,233 million Euro at the end of 2017.
  • Trade working capital moved from 644 million Euro (26% of sales) at the end of 2017 to 653 million Euro (29% of sales) at the end of the third quarter of 2018.
  • Net financial debt amounted to 99 million Euro, versus 18 million Euro at the end of 2017.
  • Net cash from operating activities amounted to minus 15 million Euro.
To read the full press relaese click here (http://hugin.info/133908/R/2224349/872167.pdf)
Financial statements in pdf format (http://hugin.info/133908/R/2224349/872170.pdf)



This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Agfa-Gevaert via Globenewswire

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2018 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.